Sasha John

As Chief Scientific Officer, Sasha has been responsible for managing operations related to assessment of ALERTS trial data, supporting post-approval study design and implementation efforts, conducting economic and quality-of-life assessment of the Guardian technology, company publications and presentations, NIH grant procurement, management of company IP, and research related to next generation products. Sasha’s background in clinical translation of medical technology includes creation of a neuroimaging based hearing assessment technology acquired by Bio-logic Systems Corp (now Natus) in 2003 which became the best-selling audiology-based product in company history. He holds 75+ US patents and has served as an IP strategy consultant in the areas of neurostimulation, neuroimaging, wireless power transmission, medical wearables, and renal nerve ablation. He has lectured at IBBME at University of Toronto since 2007 on commercialization of medical technology.

As Chief Scientist, Sasha has been responsible for managing operations related to assessment of ALERTS trial data, supporting post-approval study design and implementation efforts, conducting economic and quality-of-life assessment of the Guardian technology, company publications and presentations, NIH grant procurement, management of company IP, and research related to next generation products. Sasha’s background in clinical translation of medical technology includes creation of a neuroimaging based hearing assessment technology acquired by Bio-logic Systems Corp (now Natus) in 2003 which became the best-selling audiology-based product in company history. He holds 75+ US patents and has served as an IP strategy consultant in the areas of neurostimulation, neuroimaging, wireless power transmission, medical wearables, and renal nerve ablation. He has lectured at IBBME at University of Toronto since 2007 on commercialization of medical technology.